Fig. 4

Inhibition of IDO1 and TDO2 suppressed tumor growth in the humanized and syngeneic mouse models. A Anti-tumor activity of IDO1 inhibitor or AT-0174 in sensitive vs. resistant tumors using humanized mouse models. B IDOi significantly reduced tumor growth in the resistant tumor group (ALC); however, AT-0174 treatment resulted in greater suppression in tumor growth and weight. C-D Anti-tumor activity of IDOi or AT-0174 in sensitive vs. resistant tumors using syngeneic mouse models. D Consistent with the humanized mouse model above, a significant reduction in tumor weight and size was observed in syngeneic mice with resistant tumors treated with AT-0174. E Anti-tumor activity of AT-0174 in CRISPR direct Ido1 KO in LLC-CR tumor (LLC-CRSG2). Tumor burden was significantly suppressed by Ido1-KO and further reduced by AT-0174. Data were analyzed using one-way ANOVA followed by Tukey’s multiple comparisons for tumor growth and Dunnett’s multiple comparisons for tumor weight with *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001